Semaglutide in CFRD
NCT05788965 on ClinicalTrials.gov · last registry update 2026-01-21
A small phase 2/phase 3 — 8 participants, against a typical 60. The sponsor logged completion for 23 December 2024. Primary outcome, as filed: Weight.
- Status
- COMPLETED
- Phase
- P2/P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- University of Minnesota
- Sponsor type
- Other
- Enrollment
- 8
- Started
- 2023-10-16
- Primary completion
- 2024-12-23 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Weight
Conditions studied
Cystic Fibrosis · Cystic Fibrosis-related Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.